Nafazatrom

CAT: 0804-HY-121586Size: 1 EachDry Ice: NoHazardous: No

1 / 1

CAT#:0804-HY-121586Size:1 Each

Selected

24/48H Stock Items & 2 to 6 Weeks non Stock Items.

Quick Request Actions

Description

Nafazatrom (Bay g 6575) is an orally active cardioprotective agent that protects against ischemic damage. Nafazatrom dose-dependently inhibits neutrophil aggregation, superoxide anion generation, arachidonic acid metabolism, and to a lesser extent the release of β-glucosidase, platelet aggregation or arachidonic acid in vitro. Acid metabolism has no significant effect. In a dog ischemia-reperfusion model, Nafazatrom (10 mg/kg; po) reduced infarct size and the occurrence of arrhythmias and rescued ischemic myocardial function without affecting any hemodynamic changes. The basis of Nafazatrom's cardioprotection may be inhibition of neutrophil function and cellular infiltration in vitro[1].

CAS Number

59040-30-1

Product Name Alternative

Bay g 6575

UNSPSC

12352005

Target

Lipoxygenase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/nafazatrom.html

Smiles

O=C1N(N=C(C1)C)CCOC2=CC=C3C=CC=CC3=C2

Molecular Formula

C16H16N2O2

Molecular Weight

268.31

References & Citations

[1]Nafazatrom-induced salvage of ischemic myocardium in anesthetized dogs is mediated through inhibition of neutrophil function.

Shipping Conditions

Room temperature

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Alternative Products

Catalog	Name
GTR19193414-01	Nafazatrom

Nafazatrom

Alternative Products

Popular Products